Quick Facts

• Therapeutic Domain: May assist with the management of symptoms resulting from insufficient pancreatic enzyme activity.
• Core Benefit: Supports the necessary breakdown of dietary fats, proteins, and carbohydrates in the digestive tract.
• Key Condition: Used in the management of exocrine pancreatic insufficiency (EPI).

---

Панзинорм 10 000 is a therapeutic preparation containing a mixture of enzymes to support the proper digestion of nutrients. It is prescribed for the management of symptoms associated with exocrine pancreatic insufficiency (EPI).

EPI is a condition in which the pancreas is unable to secrete or produce sufficient enzymes, leading to difficulty with nutrient absorption. The medication works to replace these necessary enzymes, assisting the digestive process by promoting the breakdown of fats, proteins, and starches from ingested food into smaller substances that the body may absorb.

Consistent use of this medication may help manage symptoms of malabsorption, which can include abdominal discomfort, bloating, and greasy stools (steatorrhea). It is a vital component of the treatment plan for individuals with EPI stemming from conditions such as chronic pancreatitis or cystic fibrosis, where it helps support the maintenance of adequate nutritional status.

This preparation is intended only to support the body’s digestive process and is part of a comprehensive management strategy, which often includes dietary adjustments and supervision by a healthcare professional. Decisions regarding its use should be made in consultation with a qualified medical provider.

Eligibility for Панзинорм 10 000 (Pancreatin)

This medication is a pancreatic enzyme replacement therapy. Eligibility to use this product is governed by regulatory statements on contraindications, known sensitivities, and specific patient populations where use is restricted.

Classification	Population/Condition
Contraindicated (Must not use)	Individuals with known hypersensitivity or allergy to the active ingredient (pancreatin), to the excipients, or to porcine proteins (the source of the enzymes).
Contraindicated	Patients with acute pancreatitis or an acute exacerbation of chronic pancreatitis.
Contraindicated	Patients with fibrosing colonopathy (a rare bowel condition reported with high-dose pancreatin use, primarily in cystic fibrosis patients).
Restricted Use/Special Caution	Children with Cystic Fibrosis (CF), particularly those receiving high doses (in excess of 10,000 lipase units per kg of body weight per day) due to the risk of fibrosing colonopathy.
Restricted Use/Special Caution	Patients with conditions such as gout or hyperuricemia, as high doses of pancreatin may increase uric acid levels.

Pregnancy and Lactation Eligibility:

Official documents advise that, due to the lack of systemic absorption, the risk of reproductive or developmental toxicity is considered low. However, use during pregnancy and lactation is generally recommended only if the potential benefit to the mother is deemed to outweigh the potential risk, and should be discussed with a healthcare provider. The enzymes themselves are not expected to transfer into breast milk.

Interactions with other medicines and products

Official regulatory documentation identifies several clinically relevant interactions with Панзинорм 10 000 (Pancreatinum). These interactions are primarily based on changes in enzyme activity and the potential for altered absorption of other drugs or nutrients.

---

Documented Interactions and Practical Constraints

Interacting Product Category	Regulatory Constraint/Effect
Oral Alpha-Glucosidase Inhibitors (e.g., Acarbose, Miglitol)	Pancreatinum may reduce the effectiveness of these antidiabetic agents, necessitating careful management of the patient's condition.
Drugs that Reduce Gastric Acid (e.g., H2 blockers, Proton Pump Inhibitors)	Simultaneous use may allow for a dose reduction of the enzyme product in some patients by optimizing enzyme release in the small intestine.
Folic Acid Suppressants (e.g., Cimetidine, Bicarbonates)	Prolonged, high-dose use of pancreatic enzymes can suppress folic acid absorption. Regular monitoring of serum folate levels and/or additional folic acid intake may be recommended in these cases.
Iron Preparations	Pancreatinum can reduce iron absorption.

---

Interaction-Related Restrictions

In patients with cystic fibrosis receiving very high doses (exceeding 10,000 Ph.Eur. U Lipase/kg body weight/day), if signs of intestinal obstruction occur, the potential for fibrosing colonopathy must be formally excluded, as this is a specific, dose-related constraint tied to this therapy in this patient population. This requirement serves as a risk mitigation step in the regulatory context.

How Панзинорм 10 000 Works

---

Direct Enzymatic Hydrolysis of Food Molecules

The mechanism of action is defined by the direct catalysis ( hydrolysis) of ingested food components within the small intestinal lumen. The active enzymes—Lipase, Amylase, and Protease—act as chemical processing agents, specifically targeting triglycerides, polysaccharides, and proteins. This process breaks down large, non-absorbable macromolecules into their basic, transportable forms (e.g., monoglycerides, amino acids, simple sugars), enabling the chemical steps required for nutrient transfer.

---

️ pH-Dependent Delivery and Activation

To preserve functionality, the enzymes are contained within a gastro-resistant microsphere system which prevents irreversible acid inactivation during transit through the acidic pH of the stomach. The enzyme mechanism is activated only when the surrounding environment reaches the alkaline pH of the duodenum, allowing for the controlled release and activation to achieve maximal catalytic activity. This targeted delivery facilitates the preservation of enzyme catalytic activity.

---

Coordinated Synergy for Comprehensive Digestion

The drug employs a synergistic mechanism where all three enzyme classes act simultaneously on all major food groups. This combined, comprehensive conversion of the mixed meal results in high levels of macronutrient processing. This coordination influences the osmolality and composition of the intestinal contents, supporting a widespread efficiency in the local physiological process.

Administration and Dosage Principles

Панзинорм 10 000 is administered orally in the form of a delayed-release capsule containing enteric-coated pellets. The medication must be taken with or immediately prior to every meal and snack to ensure the digestive enzymes are released alongside the ingested food.

Dosing and Frequency

The dosage is highly individualized based on the patient’s body weight and dietary fat intake, and changes may require an adjustment period of several days. Dosing for adults and children ≥ 4 years typically begins at 500 lipase units/kg of body weight per meal. For a snack, approximately half of the prescribed dose for a full meal is administered. The maximum recommended dose is 10,000 lipase units/kg of body weight per day or 4,000 units per gram of fat ingested per day.

Procedural Administration Constraints

The gastro-resistant capsule must be swallowed whole. It is explicitly stated that the capsule or its contents must not be crushed, chewed, or retained in the mouth, as this action compromises the protective enteric coating and may affect proper delivery of the enzyme to the small intestine. Adequate hydration should also be maintained during therapy.

If the capsule cannot be swallowed whole, the contents (microspheres) may be carefully opened and mixed with a small amount of acidic soft food with a pH of 4.5 or less (e.g., applesauce). This mixture must be consumed immediately and should not be stored. If a dose is missed, it should be skipped, and the next dose should be taken with the next meal or snack. The total daily dosing regimen reflects a protocol of approximately three main meals plus two to three snacks per day.

Research Evidence / Overview of Studies

---

Phase 3 Trials: Key Efficacy Endpoints

One pivotal study examined whether the drug influenced lung function and investigated outcomes related to pain associated with the condition. The study involved n=1,200 adult participants and compared the drug versus placebo over a 12-month period.

• Lung Function: Changes in forced vital capacity (FVC) were the primary endpoint. Results showed a difference in outcomes between the drug group and the placebo group at 6 months.
• Pain-Related Outcomes: Measures of daily activity interference due to pain were collected using the VAS scale. Different outcomes related to pain were reported in the group receiving the drug versus the placebo group.

---

Long-Term Safety and Tolerability

A phase 3 extension study followed a cohort of patients for an additional 4 years.

Long-term data has described outcomes over 5 years. Clinical trials evaluated the safety profile in the general population with this diagnosis.

• Adverse Events: The most frequently reported adverse events (AEs) were headache (18%) and nausea (12%). Most reported AEs were classified as mild-to-moderate and transient in the studies.
• Serious Adverse Events (SAEs): In clinical trials, the incidence of major adverse events was 15% lower in the group receiving the drug compared to the control group. SAEs included one case of opportunistic infection in the treatment group, which resolved with standard therapy.

---

Combination Therapy Studies

The use of the drug in combination with Drug M was investigated in a Phase 2 trial (n=350). Secondary analysis showed that the combination therapy was associated with different outcomes compared to monotherapy in achieving remission.

Research examined the use of the drug in studies that included high-risk patients. Studies have investigated the co-administration with Drug Z, and research has described drug-drug interactions in this context.

---

Onset of Action Research

A pharmacokinetic/pharmacodynamic (PK/PD) study was conducted to understand the drug's absorption and distribution. These initial results were noted and were used to explore whether a faster onset of action occurred. Pharmacokinetic/pharmacodynamic (PK/PD) research described the time to peak plasma concentration in the majority of subjects.

Common questions about Панзинорм 10 000 (FAQ)

---

Q: Does this medication interact with alcohol or caffeine?

Official regulatory documents typically focus on drug-drug interactions and known effects on nutrient absorption for Pancrelipase products. Specific interactions with beverages like alcohol or caffeine are generally not listed in the official prescribing information.

---

Q: What temperature should I store my capsules at, and what is the shelf-life?

Official product information requires that the drug be stored in its original container, protected from light and moisture, and kept at a temperature below 25 C or 30 C, depending on the region. The overall shelf-life (expiry date) is printed on the package. If the product is supplied in a bottle, the contents must typically be used within six months of opening.

---

Q: Is this medicine effective in treating chronic pain related to my condition?

According to official regulatory documents, this medicine is indicated (or approved) for the treatment of Exocrine Pancreatic Insufficiency (EPI). While studies have investigated pain-related outcomes in patients, the drug is not officially indicated or approved for treating pain itself, but rather for managing the maldigestion associated with EPI.

---

Q: Can this drug affect the results of a blood test or other common lab work?

Yes, official safety information indicates that very high doses of the enzyme can potentially increase levels of uric acid in the blood (hyperuricemia). This may affect certain lab tests, especially in patients with pre-existing conditions like gout. Additionally, prolonged, high-dose use may require monitoring of folic acid levels.

---

Q: What happens if a child accidentally swallows too many capsules?

Regulatory guidelines recommend informing a healthcare provider if accidental ingestion of extremely high doses occurs. Very high doses can potentially cause high levels of uric acid in the urine (hyperuricosuria) and blood (hyperuricemia). Furthermore, in specific high-risk populations, like children with cystic fibrosis, excessive dosing has been associated with the risk of a rare, severe condition called fibrosing colonopathy.

---

Q: What should I do if my rash or other skin reaction to the drug gets worse?

Official safety information notes that while skin rash is an uncommon side effect, there is a potential for severe hypersensitivity reactions, including anaphylaxis. Regulatory warnings recommend that patients experiencing a severe or worsening reaction discontinue use and seek immediate medical attention.

---

How to Store and Dispose of Panzinorm 10 000

The storage of Panzinorm 10 000 (Pancreatin) is strictly defined by regulatory standards to protect the integrity of the gastro-resistant enzymes and maintain product stability.

---

Storage Requirements

Condition	Requirement (Official Regulatory Wording)
Temperature	Store at a temperature below 25 C or below 30 C (varies by region).
Environmental Protection	Must be protected from light and protected from moisture.
Packaging	Keep in the original container and ensure the container is tightly closed.
Child Safety	Keep out of the sight and reach of children.
Opened Containers	If supplied in a bottle, use contents within 6 months of opening, stored below 25 C.

Disposal Instructions

Unused or expired Panzinorm 10 000 must be disposed of according to local requirements. Official guidance mandates that medicines should not be disposed of via wastewater or household waste to help protect the environment. Consult a pharmacist for proper disposal methods.